November 25, 2025

FDA OKs First SMA Gene Replacement Therapy

The FDA approved Itvisma, the first gene replacement therapy for children 2 years and older, teens, and adults with spinal muscular atrophy, a one-time treatment that replaces the SMN1 gene and demonstrated improved motor function in Phase 3 studies.

Conexiant

November 13, 2025

Allergies May Increase Surgical Risk

Researchers show that patients with allergies face higher postoperative risks.

Conexiant

April 29, 2025

What Surgeons Should Say During Awake Surgery

Study identifies specific terminology and communication strategies to enhance patient experience in wide-awake hand procedures

Conexiant

May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

August 19, 2025

Neck Swelling, Dysphagia, and Jaw Pain: What’s Your Diagnosis?

A rare carotid artery pseudoaneurysm complicated by MRSA infection, septic arthritis, and an incidental thigh tumor challenged clinicians but was successfully treated with surgery and targeted antibiotics.

Conexiant

September 09, 2025

Merger Cure? Rural Hospitals Try Networks

Mobile magnetic resonance imaging units and rural hospital networks support independent hospitals in improving access to diagnostic imaging and patient care in underserved areas.

KFF Health News

October 29, 2025

Unstable Sitting Replicated Real-World Lumbar Posture

Unstable sitting mirrors natural lumbar alignment tracked over 2 days.

Conexiant

August 01, 2025

Dynamic Splinting More Effective Than Diapering in Infant Hip Development

A new study combining cohort data and meta-analysis found that dynamic splinting and double diapering were more effective than observation for improving alpha angle and hip maturation in infants under 6 months old.

Conexiant

September 03, 2025

FDA Approves Denosumab Biosimilars

The FDA approved Bildyos and Bilprevda are providing new options comparable to Prolia and Xgeva for osteoporosis, cancer-related bone disease, and other skeletal conditions.

Conexiant